AZ’s COVID-19 jab sales top $1.2bn, but come at a lossAstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in Share XAZ’s COVID-19 jab sales top $1.2bn, but come at a losshttps://pharmaphorum.com/news/azs-covid-19-jab-sales-top-1-2bn-but-come-at-a-loss/
Patients in England get fast access to AZ’s Tagrisso in early lung cancerThe UK’s drugs regulator has swiftly granted a licence extension for AstraZeneca’s Tagrisso in certain patients with early Share XPatients in England get fast access to AZ’s Tagrisso in early lung cancerhttps://pharmaphorum.com/news/patients-in-england-get-fast-access-to-azs-tagrisso-in-early-lung-cancer/
AZ’s Tagrisso gets new early lung cancer use in USAstraZeneca’s Tagrisso (osimertinib) has been approved by the FDA in a new lung cancer indication that extends its Share XAZ’s Tagrisso gets new early lung cancer use in UShttps://pharmaphorum.com/news/azs-tagrisso-gets-new-early-lung-cancer-use-in-us/
J&J files lung cancer bispecific amivantamab for FDA approvalJohnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big Share XJ&J files lung cancer bispecific amivantamab for FDA approvalhttps://pharmaphorum.com/news/jj-files-lung-cancer-bispecific-amivantamab-for-fda-approval/
Genprex cancer gene therapy paired with AZ, Merck lung cancer drugsAn experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Share XGenprex cancer gene therapy paired with AZ, Merck lung cancer drugshttps://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/
FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerThe FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung Share XFDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerhttps://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/
Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerUK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell Share XPrice cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerhttps://pharmaphorum.com/news/price-cut-wins-nice-ok-for-azs-tagrisso-in-untreated-lung-cancer/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
